Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The pentoxifylline experience: exercise testing reconsidered

F Lindgärde1, K H Labs, M Rössner

  • 1Department of Vascular and Renal Diseases, University Hospital, Malmö, Sweden.

Vascular Medicine (London, England)
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common variant at 16p11.2 conferring risk of psychosis.

Molecular psychiatry·2012
Same author

[Pathowiki. A free expert database for pathology].

Der Pathologe·2012
Same author

Plasma lipid fatty acid composition, desaturase activities and insulin sensitivity in Amerindian women.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2010
Same author

Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study.

Thorax·2008
Same author

Plasma levels of complement C3 is associated with development of hypertension: a longitudinal cohort study.

Journal of human hypertension·2006
Same author

Fatality of acute coronary events in relation to hypertension and low-grade inflammation: a population-based cohort study.

Journal of human hypertension·2006
Same journal

Images in Vascular Medicine: When coronary anatomy goes the wrong way-A diagnostic challenge.

Vascular medicine (London, England)·2026
Same journal

Home-based intravenous iloprost by portable elastomeric pump in chronic limb-threatening ischemia: A pilot study.

Vascular medicine (London, England)·2026
Same journal

Vascular Disease Patient Information Page: Renal denervation.

Vascular medicine (London, England)·2026
Same journal

Relations of Life's Essential 8 score with arterial and microvascular function: The Jackson Heart Study.

Vascular medicine (London, England)·2026
Same journal

Generalizability of the CREST‑2 trial: A real‑world analysis.

Vascular medicine (London, England)·2026
Same journal

Downhill-walking exercise training in a patient with symptomatic peripheral artery disease: A case report.

Vascular medicine (London, England)·2026
See all related articles

This review examines clinical trial methods for chronic occlusive arterial disease (COAD) stage II, focusing on treadmill settings, valid endpoints, and patient response factors. It discusses clinically relevant improvements in claudication distance for treatment effectiveness in COAD patients.

Area of Science:

  • Vascular Medicine
  • Clinical Trial Methodology
  • Pharmacoeconomics

Background:

  • Chronic occlusive arterial disease (COAD) stage II, characterized by intermittent claudication, presents challenges in clinical trial design.
  • Standardized methodologies are crucial for evaluating treatment efficacy in these patients.

Purpose of the Study:

  • To critically review and discuss the methodology of clinical trials for intermittent claudication.
  • To emphasize valid trial endpoints and identify factors influencing treatment response in COAD patients.

Main Methods:

  • Review of internationally accepted standard treadmill settings and their limitations.
  • Discussion of hemodynamic surrogates and clinically oriented parameters as valid trial endpoints.
  • Analysis of spontaneous improvements and patient variables for defining treatment responder populations.

Related Experiment Videos

Main Results:

  • Identification of key variables for defining patient subgroups with high treatment response.
  • Evaluation of clinically relevant claudication distance improvement based on EU guidelines.
  • Presentation of pentoxifylline results within the context of discussed methodological variables.

Conclusions:

  • Standardized treadmill protocols and appropriate endpoints are vital for reliable COAD clinical trials.
  • Defining patient responder populations can enhance the interpretation of treatment effects.
  • Methodological rigor is essential for assessing clinically meaningful improvements in intermittent claudication.